Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

DALLAS Millions of women may be unknowingly living with risk factors for heart, kidney and metabolic disease interconnected ...

Data across obesity, cardiovascular disease ... Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious ...

executive vice president of Product & Portfolio Strategy at Novo Nordisk. "Our investment into the understanding and treatment of obesity continues to reveal new insights, with semaglutide showing its ...